$265,316,226

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

ACTION DATE2026-03-02·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00001_7505_-NONE-_-NONE-

Award description

ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Develop and procure antibiotic treatments for biodefense against biothreat pathogens.

Sub-sectors

pharmaceutical-developmentbiosecurityantimicrobial-resistance

Why this matters

Addresses critical gap in medical countermeasures for biological threats to national security and public health.

Supply-chain signal

Signals demand for domestic pharmaceutical manufacturing capacity and active pharmaceutical ingredient (API) production for strategic reserves.

U.S.–China competition angle

Reduces U.S. dependence on foreign sources for critical antibiotics; counters China's dominance in API manufacturing for essential medicines.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-14. Cost: $0.001336.

Period of performance

Start

2019-12-18

End

2029-12-17

Status

activein 1312 days

Sources

Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00001_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.